Khek YuK.Y.HoKhek YuK.Y. i inni, Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers, „Journal of Gastroenterology”, 44 (7), 2009, s. 697–707, DOI: 10.1007/s00535-009-0072-4, PMID: 19434360 [dostęp 2022-01-17](ang.).
ElaineE.ChongElaineE., Mary H.H.M.H.H.EnsomMary H.H.M.H.H., Pharmacogenetics of the proton pump inhibitors: a systematic review, „Pharmacotherapy”, 23 (4), 2003, s. 460–471, DOI: 10.1592/phco.23.4.460.32128, PMID: 12680476 [dostęp 2022-01-17](ang.).
L.B.L.B.GersonL.B.L.B., G.G.TriadafilopoulosG.G., Proton pump inhibitors and their drug interactions: an evidence-based approach, „European Journal of Gastroenterology & Hepatology”, 13 (5), 2001, s. 611–616, DOI: 10.1097/00042737-200105000-00025, PMID: 11396546 [dostęp 2022-01-17](ang.).
Ian J.I.J.SimpsonIan J.I.J. i inni, Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases, „Nephrology”, 11 (5), 2006, s. 381–385, DOI: 10.1111/j.1440-1797.2006.00651.x, PMID: 17014549 [dostęp 2022-01-17](ang.).
E.J.E.J.KuipersE.J.E.J. i inni, Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication, „The New England Journal of Medicine”, 334 (16), 1996, s. 1018–1022, DOI: 10.1056/NEJM199604183341603, PMID: 8598839 [dostęp 2022-01-17](ang.).
SandraS.DialSandraS., KhalidK.AlrasadiKhalidK., ChantalCh.ManoukianChantalCh., AllenA.HuangAllenA., DickD.MenziesDickD., Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies, „Canadian Medical Association Journal”, 171 (1), 2004, s. 33–38, DOI: 10.1503/cmaj.1040876, PMID: 15238493, PMCID: PMC437681 [dostęp 2022-01-17](ang.).
JenniferJ.LeonardJenniferJ., John K.J.K.MarshallJohn K.J.K., PaulP.MoayyediPaulP., Systematic review of the risk of enteric infection in patients taking acid suppression, „The American Journal of Gastroenterology”, 102 (9), 2007, 2047–2056; quiz 2057, DOI: 10.1111/j.1572-0241.2007.01275.x, PMID: 17509031 [dostęp 2022-01-17](ang.).
Yu-XiaoY.X.YangYu-XiaoY.X., James D.J.D.LewisJames D.J.D., SolomonS.EpsteinSolomonS., David C.D.C.MetzDavid C.D.C., Long-term proton pump inhibitor therapy and risk of hip fracture, „Journal of the American Medical Association”, 296 (24), 2006, s. 2947–2953, DOI: 10.1001/jama.296.24.2947, PMID: 17190895 [dostęp 2022-01-17](ang.).
S.A.S.A.WatsonS.A.S.A. i inni, Potential role of endocrine gastrin in the colonic adenoma carcinoma sequence, „British Journal of Cancer”, 87 (5), 2002, s. 567–573, DOI: 10.1038/sj.bjc.6600509, PMID: 12189558, PMCID: PMC2376163 [dostęp 2022-01-17](ang.).
F.W.F.W.GreenF.W.F.W., M.M.M.M.KaplanM.M.M.M., L.E.L.E.CurtisL.E.L.E., P.H.P.H.LevineP.H.P.H., Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage, „Gastroenterology”, 74 (1), 1978, s. 38–43, DOI: 10.1016/0016-5085(78)90352-9, PMID: 21830 [dostęp 2022-01-17](ang.).
J. MarkJ.M.RuscinJ. MarkJ.M., Robert LeeR.L.PageRobert LeeR.L., Robert J.R.J.ValuckRobert J.R.J., Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor, „The Annals of Pharmacotherapy”, 36 (5), 2002, s. 812–816, DOI: 10.1345/aph.10325, PMID: 11978157 [dostęp 2022-01-17](ang.).
HenningH.BlumeHenningH., FrankF.DonathFrankF., AndréA.WarnkeAndréA., Barbara S.B.S.SchugBarbara S.B.S., Pharmacokinetic drug interaction profiles of proton pump inhibitors, „Drug Safety”, 29 (9), 2006, s. 769–784, DOI: 10.2165/00002018-200629090-00002, PMID: 16944963 [dostęp 2022-01-17](ang.).
T.J.T.J.HumphriesT.J.T.J., Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole, „Digestive Diseases and Sciences”, 36 (12), 1991, s. 1665–1669, DOI: 10.1007/BF01296606, PMID: 1748033 [dostęp 2022-01-17](ang.).
R.K.R.K.DixitR.K.R.K., A.B.A.B.ChawlaA.B.A.B., N.N.KumarN.N., S.K.S.K.GargS.K.S.K., Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers, „Methods and Findings in Experimental and Clinical Pharmacology”, 23 (1), 2001, s. 37–39, DOI: 10.1358/mf.2001.23.1.619178, PMID: 11413862 [dostęp 2022-01-17](ang.).
J. DeJ.D.GraefJ. DeJ.D., M.C.M.C.Woussen-ColleM.C.M.C., Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs, „Gastroenterology”, 91 (2), 1986, s. 333–337, DOI: 10.1016/0016-5085(86)90565-2, PMID: 2873074 [dostęp 2022-01-17](ang.).
JesperJ.HallasJesperJ. i inni, Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study, „BMJ (Clinical research ed.)”, 333 (7571), 2006, s. 726, DOI: 10.1136/bmj.38947.697558.AE, PMID: 16984924, PMCID: PMC1592384 [dostęp 2022-01-17](ang.).
Deepak L.D.L.BhattDeepak L.D.L. i inni, ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, „Journal of the American College of Cardiology”, 52 (18), 2008, s. 1502–1517, DOI: 10.1016/j.jacc.2008.08.002, PMID: 19017521 [dostęp 2022-01-17](ang.).
M.M.GilardM.M., B.B.ArnaudB.B., G. LeG.L.GalG. LeG.L., J.F.J.F.AbgrallJ.F.J.F., J.J.BoschatJ.J., Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin, „Journal of Thrombosis and Haemostasis”, 4 (11), 2006, s. 2508–2509, DOI: 10.1111/j.1538-7836.2006.02162.x, PMID: 16898956 [dostęp 2022-01-17](ang.).
MartineM.GilardMartineM. i inni, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study, „Journal of the American College of Cardiology”, 51 (3), 2008, s. 256–260, DOI: 10.1016/j.jacc.2007.06.064, PMID: 18206732 [dostęp 2022-01-17](ang.).
David N.D.N.JuurlinkDavid N.D.N. i inni, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel, „Canadian Medical Association journal”, 180 (7), 2009, s. 713–718, DOI: 10.1503/cmaj.082001, PMID: 19176635, PMCID: PMC2659819 [dostęp 2022-01-17](ang.).
EdmundE.PezallaEdmundE., DavidD.DayDavidD., IndiraI.PulliadathIndiraI., Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors, „Journal of the American College of Cardiology”, 52 (12), 2008, 1038–1039; author reply 1039, DOI: 10.1016/j.jacc.2008.05.053, PMID: 18786491 [dostęp 2022-01-17](ang.).
Xue-QingX.Q.LiXue-QingX.Q., Tommy B.T.B.AnderssonTommy B.T.B., MarieM.AhlströmMarieM., LarsL.WeidolfLarsL., Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities, „Drug Metabolism and Disposition: The Biological Fate of Chemicals”, 32 (8), 2004, s. 821–827, DOI: 10.1124/dmd.32.8.821, PMID: 15258107 [dostęp 2022-01-17](ang.).
PaulP.MoayyediPaulP., Daniel C.D.C.SadowskiDaniel C.D.C., Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data?, „Canadian Journal of Gastroenterology”, 23 (4), 2009, s. 251–252, DOI: 10.1155/2009/868946, PMID: 19373416, PMCID: PMC2711671 [dostęp 2022-01-17](ang.).
GeorgeG.SachsGeorgeG., Jai MooJ.M.ShinJai MooJ.M., The basis of differentiation of PPIs, „Drugs of Today (Barcelona, Spain: 1998)”, 40 Suppl A, 2004, s. 9–14, PMID: 15190382 [dostęp 2022-01-17](ang.).
C.W.C.W.HowdenC.W.C.W., Clinical pharmacology of omeprazole, „Clinical Pharmacokinetics”, 20 (1), 1991, s. 38–49, DOI: 10.2165/00003088-199120010-00003, PMID: 2029801 [dostęp 2022-01-17](ang.).
Khek YuK.Y.HoKhek YuK.Y. i inni, Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers, „Journal of Gastroenterology”, 44 (7), 2009, s. 697–707, DOI: 10.1007/s00535-009-0072-4, PMID: 19434360 [dostęp 2022-01-17](ang.).
ElaineE.ChongElaineE., Mary H.H.M.H.H.EnsomMary H.H.M.H.H., Pharmacogenetics of the proton pump inhibitors: a systematic review, „Pharmacotherapy”, 23 (4), 2003, s. 460–471, DOI: 10.1592/phco.23.4.460.32128, PMID: 12680476 [dostęp 2022-01-17](ang.).
L.B.L.B.GersonL.B.L.B., G.G.TriadafilopoulosG.G., Proton pump inhibitors and their drug interactions: an evidence-based approach, „European Journal of Gastroenterology & Hepatology”, 13 (5), 2001, s. 611–616, DOI: 10.1097/00042737-200105000-00025, PMID: 11396546 [dostęp 2022-01-17](ang.).
Ian J.I.J.SimpsonIan J.I.J. i inni, Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases, „Nephrology”, 11 (5), 2006, s. 381–385, DOI: 10.1111/j.1440-1797.2006.00651.x, PMID: 17014549 [dostęp 2022-01-17](ang.).
E.J.E.J.KuipersE.J.E.J. i inni, Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication, „The New England Journal of Medicine”, 334 (16), 1996, s. 1018–1022, DOI: 10.1056/NEJM199604183341603, PMID: 8598839 [dostęp 2022-01-17](ang.).
SandraS.DialSandraS., KhalidK.AlrasadiKhalidK., ChantalCh.ManoukianChantalCh., AllenA.HuangAllenA., DickD.MenziesDickD., Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies, „Canadian Medical Association Journal”, 171 (1), 2004, s. 33–38, DOI: 10.1503/cmaj.1040876, PMID: 15238493, PMCID: PMC437681 [dostęp 2022-01-17](ang.).
JenniferJ.LeonardJenniferJ., John K.J.K.MarshallJohn K.J.K., PaulP.MoayyediPaulP., Systematic review of the risk of enteric infection in patients taking acid suppression, „The American Journal of Gastroenterology”, 102 (9), 2007, 2047–2056; quiz 2057, DOI: 10.1111/j.1572-0241.2007.01275.x, PMID: 17509031 [dostęp 2022-01-17](ang.).
Yu-XiaoY.X.YangYu-XiaoY.X., James D.J.D.LewisJames D.J.D., SolomonS.EpsteinSolomonS., David C.D.C.MetzDavid C.D.C., Long-term proton pump inhibitor therapy and risk of hip fracture, „Journal of the American Medical Association”, 296 (24), 2006, s. 2947–2953, DOI: 10.1001/jama.296.24.2947, PMID: 17190895 [dostęp 2022-01-17](ang.).
S.A.S.A.WatsonS.A.S.A. i inni, Potential role of endocrine gastrin in the colonic adenoma carcinoma sequence, „British Journal of Cancer”, 87 (5), 2002, s. 567–573, DOI: 10.1038/sj.bjc.6600509, PMID: 12189558, PMCID: PMC2376163 [dostęp 2022-01-17](ang.).
F.W.F.W.GreenF.W.F.W., M.M.M.M.KaplanM.M.M.M., L.E.L.E.CurtisL.E.L.E., P.H.P.H.LevineP.H.P.H., Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage, „Gastroenterology”, 74 (1), 1978, s. 38–43, DOI: 10.1016/0016-5085(78)90352-9, PMID: 21830 [dostęp 2022-01-17](ang.).
J. MarkJ.M.RuscinJ. MarkJ.M., Robert LeeR.L.PageRobert LeeR.L., Robert J.R.J.ValuckRobert J.R.J., Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor, „The Annals of Pharmacotherapy”, 36 (5), 2002, s. 812–816, DOI: 10.1345/aph.10325, PMID: 11978157 [dostęp 2022-01-17](ang.).
HenningH.BlumeHenningH., FrankF.DonathFrankF., AndréA.WarnkeAndréA., Barbara S.B.S.SchugBarbara S.B.S., Pharmacokinetic drug interaction profiles of proton pump inhibitors, „Drug Safety”, 29 (9), 2006, s. 769–784, DOI: 10.2165/00002018-200629090-00002, PMID: 16944963 [dostęp 2022-01-17](ang.).
T.J.T.J.HumphriesT.J.T.J., Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole, „Digestive Diseases and Sciences”, 36 (12), 1991, s. 1665–1669, DOI: 10.1007/BF01296606, PMID: 1748033 [dostęp 2022-01-17](ang.).
R.K.R.K.DixitR.K.R.K., A.B.A.B.ChawlaA.B.A.B., N.N.KumarN.N., S.K.S.K.GargS.K.S.K., Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers, „Methods and Findings in Experimental and Clinical Pharmacology”, 23 (1), 2001, s. 37–39, DOI: 10.1358/mf.2001.23.1.619178, PMID: 11413862 [dostęp 2022-01-17](ang.).
J. DeJ.D.GraefJ. DeJ.D., M.C.M.C.Woussen-ColleM.C.M.C., Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs, „Gastroenterology”, 91 (2), 1986, s. 333–337, DOI: 10.1016/0016-5085(86)90565-2, PMID: 2873074 [dostęp 2022-01-17](ang.).
JesperJ.HallasJesperJ. i inni, Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study, „BMJ (Clinical research ed.)”, 333 (7571), 2006, s. 726, DOI: 10.1136/bmj.38947.697558.AE, PMID: 16984924, PMCID: PMC1592384 [dostęp 2022-01-17](ang.).
Deepak L.D.L.BhattDeepak L.D.L. i inni, ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, „Journal of the American College of Cardiology”, 52 (18), 2008, s. 1502–1517, DOI: 10.1016/j.jacc.2008.08.002, PMID: 19017521 [dostęp 2022-01-17](ang.).
M.M.GilardM.M., B.B.ArnaudB.B., G. LeG.L.GalG. LeG.L., J.F.J.F.AbgrallJ.F.J.F., J.J.BoschatJ.J., Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin, „Journal of Thrombosis and Haemostasis”, 4 (11), 2006, s. 2508–2509, DOI: 10.1111/j.1538-7836.2006.02162.x, PMID: 16898956 [dostęp 2022-01-17](ang.).
MartineM.GilardMartineM. i inni, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study, „Journal of the American College of Cardiology”, 51 (3), 2008, s. 256–260, DOI: 10.1016/j.jacc.2007.06.064, PMID: 18206732 [dostęp 2022-01-17](ang.).
David N.D.N.JuurlinkDavid N.D.N. i inni, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel, „Canadian Medical Association journal”, 180 (7), 2009, s. 713–718, DOI: 10.1503/cmaj.082001, PMID: 19176635, PMCID: PMC2659819 [dostęp 2022-01-17](ang.).
EdmundE.PezallaEdmundE., DavidD.DayDavidD., IndiraI.PulliadathIndiraI., Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors, „Journal of the American College of Cardiology”, 52 (12), 2008, 1038–1039; author reply 1039, DOI: 10.1016/j.jacc.2008.05.053, PMID: 18786491 [dostęp 2022-01-17](ang.).
Xue-QingX.Q.LiXue-QingX.Q., Tommy B.T.B.AnderssonTommy B.T.B., MarieM.AhlströmMarieM., LarsL.WeidolfLarsL., Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities, „Drug Metabolism and Disposition: The Biological Fate of Chemicals”, 32 (8), 2004, s. 821–827, DOI: 10.1124/dmd.32.8.821, PMID: 15258107 [dostęp 2022-01-17](ang.).
PaulP.MoayyediPaulP., Daniel C.D.C.SadowskiDaniel C.D.C., Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data?, „Canadian Journal of Gastroenterology”, 23 (4), 2009, s. 251–252, DOI: 10.1155/2009/868946, PMID: 19373416, PMCID: PMC2711671 [dostęp 2022-01-17](ang.).